98%
921
2 minutes
20
The pathogenesis of Alzheimer's disease (AD) involves a key event which changes the morphology of amyloid-β 42 (Aβ)₄₂ peptide from its soluble monomeric form into the fibrillated aggregates in the brain. Aluminum ion, Al(III), is known to act as a pathological chaperone of the Aβ₄₂ in this process; curcumin, a natural phenolic compound, is considered capable of binding Al(III) and Aβ₄₂; nevertheless, little is known about the combined action of curcumin and Al(III) on the Aβ₄₂ fibrillation and neurotoxicity. Here, combinations of circular dichroism spectroscopy, thioflavin T fluorescence, atomic force microscopy, Bradford and MTT assays, it is demonstrated that although Al(III) can promote the Aβ₄₂ fibrillation dose-dependently, leading to the high neurotoxicity to PC12 cells, curcumin can inhibit the events. Besides, we found that curcumin is able not only to inhibit the formation of Al(III)-induced Aβ₄₂ fibrillation, but also to form the Al(III)-curcumin complexes which in turn can remold the preformed, mature, ordered Aβ₄₂ fibrils into the low toxic amorphous aggregates. These findings suggest that curcumin could block the binding of Al(III) with Aβ₄₂ and form the Al(III)-curcumin complexes, so as to inhibit the Al(III)-induced Aβ₄₂ fibrillation and neurotoxicity. The Al(III)-curcumin complexes are worth potentially developing as a therapy agent against the neurodegenerative disorders in the future.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bbadis.2012.04.015 | DOI Listing |
Lancet Digit Health
September 2025
Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; NIHR Biomedical Research Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Background: New-onset atrial fibrillation, a condition associated with adverse outcomes in the short and long term, is common in patients admitted to intensive care units (ICUs). Identifying patients at high risk could inform trials of preventive interventions and help to target such interventions. We aimed to develop and externally validate a prediction model for new-onset atrial fibrillation in patients admitted to ICUs.
View Article and Find Full Text PDFHeart
September 2025
Department of Cardiology, University of Ulsan College of Medicine, Seoul, Korea (the Republic of)
Objective: The impact of off-label underdosing of direct oral anticoagulants (DOACs) on clinical outcomes in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) remains unclear.
Methods: The EPIC-CAD trial (Edoxaban vs Edoxaban with antiPlatelet agent In patients with atrial fibrillation and Chronic stable Coronary Artery Disease) randomised patients with AF and stable CAD to receive either edoxaban monotherapy or dual antithrombotic therapy (edoxaban plus single antiplatelet agent). Off-label underdosing was defined as low-dose edoxaban (30 mg once daily) without standard criteria for dose reduction.
Europace
September 2025
Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
Thromb Haemost
September 2025
Biomedical Department of Internal and Specialist Medicine, University of Palermo, Palermo, Italy.
Background: Atrial fibrillation (AF) is the most common arrhythmia in adults, with incidence increasing with age. Cognitive impairment (CoI) and dementia share risk factors with AF. Meta-analyses indicate that AF increases the risk of CoI by 2.
View Article and Find Full Text PDF